The effect of Carnitine on plasma Albomin level in haemodialysis patient
Phase 2
- Conditions
- haemodialysis patients.End-stage renal disease
- Registration Number
- IRCT138804092106N1
- Lead Sponsor
- Isfahan university of medical sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
age upper than 21, have history of haemodialysis at least for one month before, having informed consent, no history of carnitine use in previous 8 weeks, no history of infectious disease or fever in previous month.
Exclusion criteria: having side effects after taking tablets (like hypertension, dizziness, blurred vision, minimental status and diarrhea), person who want to exit from the staudy,having an infectious problem or antibiotic usage or if a patient change the dialysis method, migrate from the center, having renal transplantation .
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Albomin of plasma. Timepoint: 1 month. Method of measurement: Bromocrosol Green method.
- Secondary Outcome Measures
Name Time Method Side effects. Timepoint: evrey month. Method of measurement: questionnair.;Hemoglobin. Timepoint: every month. Method of measurement: automated analyzer.